Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Diabetes, Obesity & Metabolism
|
January 22, 2019
Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
Emilie H Zobel, Bernt J von Scholten, Bryan Goldman, et al.
The American Journal of Surgical Pathology
|
March 15, 2014
Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study
James R Cook, Bryan Goldman, Raymond R Tubbs, et al.
Obesity (Silver Spring, Md.)
|
November 21, 2023
Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis
Robert F Kushner, Anders Fink-Jensen, Ofir Frenkel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 16, 2010
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)
Philip J Gold, Bryan Goldman, Syma Iqbal, et al.
Clinical Genitourinary Cancer
|
May 27, 2008
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy
Tomasz M Beer, Bryan Goldman, Craig R Nichols, et al.
Circulation
|
December 20, 2018
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
The Journal of Urology
|
September 18, 2007
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
R Bruce Montgomery, Bryan Goldman, Catherine M Tangen, et al.
Circulation
|
May 29, 2019
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"
Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
JAMA Internal Medicine
|
September 3, 2024
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials
Thomas A Wadden, Gregory K Brown, Christina Egebjerg, et al.
The Journal of Urology
|
October 22, 2008
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794
Gregory P Swanson, Bryan Goldman, Catherine M Tangen, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Diabetes, Obesity & Metabolism
|
January 22, 2019
Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
Emilie H Zobel, Bernt J von Scholten, Bryan Goldman, et al.
The American Journal of Surgical Pathology
|
March 15, 2014
Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study
James R Cook, Bryan Goldman, Raymond R Tubbs, et al.
Obesity (Silver Spring, Md.)
|
November 21, 2023
Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis
Robert F Kushner, Anders Fink-Jensen, Ofir Frenkel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 16, 2010
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)
Philip J Gold, Bryan Goldman, Syma Iqbal, et al.
Clinical Genitourinary Cancer
|
May 27, 2008
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy
Tomasz M Beer, Bryan Goldman, Craig R Nichols, et al.
Circulation
|
December 20, 2018
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
The Journal of Urology
|
September 18, 2007
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
R Bruce Montgomery, Bryan Goldman, Catherine M Tangen, et al.
Circulation
|
May 29, 2019
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"
Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
JAMA Internal Medicine
|
September 3, 2024
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials
Thomas A Wadden, Gregory K Brown, Christina Egebjerg, et al.
The Journal of Urology
|
October 22, 2008
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794
Gregory P Swanson, Bryan Goldman, Catherine M Tangen, et al.
Page
of 4